Russia begins production of cancer vaccine trial

Published at: 10/12/2025 11:13 AM

The Gamaleya National Epidemiology and Microbiology Research Center has announced the production of the first three validation series of a cancer vaccine, carried out at its new drug production plant in Russia.

The director of the entity, Alexander Gintsburg, specified that the development is based on messenger RNA technology, considered one of the most advanced platforms for the creation of innovative therapies.

During a conference at the Russian Academy of Sciences, Guintsburg highlighted that the facility for mRNA vaccines is now operational and equipped, which has allowed the start of experimental production.

The center also has the necessary authorizations to apply this technology in the oncology field, from diagnosis to administration of vaccines to patients.

Mazo News Team